Physician profile
James E Mark
NPI 1841206885
$6,205.46
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $361 · 2021: $662 · 2022: $745 · 2023: $2,939 · 2024: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,662 · Food and Beverage: $1,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,662.33 |
| Food and Beverage | $1,657.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,714.96 | 2022-2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals Lp | $893.39 | 2019-2024 | Lynparza, Calquence, Tagrisso |
| Merck Sharp & Dohme LLC | $508.94 | 2019-2024 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $473.71 | 2021-2023 | Jemperli, Shingrix, Zejula |
| Biom'Up Sa | $299.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $201.15 | 2019-2024 | |
| Eisai INC. | $199.57 | 2022-2023 | |
| Myriad Genetic Laboratories, INC. | $193.97 | 2021-2023 | Precisetumor |
| Daiichi Sankyo INC. | $164.26 | 2019-2023 | Injectafer |
| Seagen INC. | $151.90 | 2020-2023 | Tivdak |
| Amgen INC. | $133.86 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.41 | 2022-2024 | Iclusig, Alunbrig, Ninlaro |
| Karyopharm Therapeutics INC. | $114.06 | 2021-2023 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $101.64 | 2019-2020 | |
| Incyte Corporation | $96.48 | 2021-2024 | Jakafi |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.